Loading…

Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions

We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the conc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular biology 2015-09, Vol.427 (19), p.3110-3122
Main Authors: Sørensen, Hans Peter, Xu, Peng, Jiang, Longguang, Kromann-Hansen, Tobias, Jensen, Knud J., Huang, Mingdong, Andreasen, Peter A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3
cites cdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3
container_end_page 3122
container_issue 19
container_start_page 3110
container_title Journal of molecular biology
container_volume 427
creator Sørensen, Hans Peter
Xu, Peng
Jiang, Longguang
Kromann-Hansen, Tobias
Jensen, Knud J.
Huang, Mingdong
Andreasen, Peter A.
description We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy. [Display omitted] •The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.
doi_str_mv 10.1016/j.jmb.2015.08.005
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1715659932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022283615004507</els_id><sourcerecordid>1715659932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</originalsourceid><addsrcrecordid>eNp9kcFu3CAURVHVKplO8wHdVCy7sQvYOLa6SqJME2mkRkq6RhieM29qgwueVLPrPyRf2C8p1qRZZoUQhwPvXkI-cpZzxqsv23w7tLlgXOaszhmTb8iCs7rJ6qqo35IFY0Jkoi6qY_I-xi1LRFHWR-RYVKLmp5wvyNMt9GAm9I76jl7h_SY76zp0OO3pDYwTWjT0FgI6oDfBT6Aj0Gu3wRYnHyL9jdMm7U2YDyw9R2fR3dNLNwU_7mkX_EA1PdfmZ7bqcaRrbIMO-_mxgx7-_nl8Ea92Mf0kfiDvOt1HOHlel-TH6vLu4ipbf_92fXG2zkwpiikTtjFclsZKbgS0WrRMCyaFZMxqDsbIohWlLUVjteZNwYFZA_q04EIzU-liST4fvGPwv3YQJzVgNND32oHfRZUikpVsmkIklB9QE3yMATo1BhzSJIozNZehtiqVoeYyFKvVHPWSfHrW79oB7MuN_-kn4OsBgDTkA0JQ0SA4AxZDKkVZj6_o_wFq1Z1X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1715659932</pqid></control><display><type>article</type><title>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</title><source>ScienceDirect Freedom Collection</source><creator>Sørensen, Hans Peter ; Xu, Peng ; Jiang, Longguang ; Kromann-Hansen, Tobias ; Jensen, Knud J. ; Huang, Mingdong ; Andreasen, Peter A.</creator><creatorcontrib>Sørensen, Hans Peter ; Xu, Peng ; Jiang, Longguang ; Kromann-Hansen, Tobias ; Jensen, Knud J. ; Huang, Mingdong ; Andreasen, Peter A.</creatorcontrib><description>We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy. [Display omitted] •The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.</description><identifier>ISSN: 0022-2836</identifier><identifier>EISSN: 1089-8638</identifier><identifier>DOI: 10.1016/j.jmb.2015.08.005</identifier><identifier>PMID: 26281711</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Amino Acid Sequence ; Animals ; Cell Line ; conformation ; Crystallography, X-Ray ; Drug Discovery ; Entropy ; fusion protein ; glycine ; Humans ; Mice ; Molecular Sequence Data ; mupain-1 ; Peptide Library ; Peptides, Cyclic - chemistry ; Peptides, Cyclic - metabolism ; Peptides, Cyclic - pharmacology ; phage display ; Protein Conformation ; Recombinant Fusion Proteins - chemistry ; Recombinant Fusion Proteins - metabolism ; Serine Endopeptidases - chemistry ; Serine Endopeptidases - metabolism ; Serine Proteinase Inhibitors - chemistry ; Serine Proteinase Inhibitors - metabolism ; Serine Proteinase Inhibitors - pharmacology ; Urokinase-Type Plasminogen Activator - antagonists &amp; inhibitors ; Urokinase-Type Plasminogen Activator - chemistry ; Urokinase-Type Plasminogen Activator - metabolism</subject><ispartof>Journal of molecular biology, 2015-09, Vol.427 (19), p.3110-3122</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</citedby><cites>FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</cites><orcidid>0000-0003-0085-9141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26281711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sørensen, Hans Peter</creatorcontrib><creatorcontrib>Xu, Peng</creatorcontrib><creatorcontrib>Jiang, Longguang</creatorcontrib><creatorcontrib>Kromann-Hansen, Tobias</creatorcontrib><creatorcontrib>Jensen, Knud J.</creatorcontrib><creatorcontrib>Huang, Mingdong</creatorcontrib><creatorcontrib>Andreasen, Peter A.</creatorcontrib><title>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</title><title>Journal of molecular biology</title><addtitle>J Mol Biol</addtitle><description>We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy. [Display omitted] •The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Cell Line</subject><subject>conformation</subject><subject>Crystallography, X-Ray</subject><subject>Drug Discovery</subject><subject>Entropy</subject><subject>fusion protein</subject><subject>glycine</subject><subject>Humans</subject><subject>Mice</subject><subject>Molecular Sequence Data</subject><subject>mupain-1</subject><subject>Peptide Library</subject><subject>Peptides, Cyclic - chemistry</subject><subject>Peptides, Cyclic - metabolism</subject><subject>Peptides, Cyclic - pharmacology</subject><subject>phage display</subject><subject>Protein Conformation</subject><subject>Recombinant Fusion Proteins - chemistry</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>Serine Endopeptidases - chemistry</subject><subject>Serine Endopeptidases - metabolism</subject><subject>Serine Proteinase Inhibitors - chemistry</subject><subject>Serine Proteinase Inhibitors - metabolism</subject><subject>Serine Proteinase Inhibitors - pharmacology</subject><subject>Urokinase-Type Plasminogen Activator - antagonists &amp; inhibitors</subject><subject>Urokinase-Type Plasminogen Activator - chemistry</subject><subject>Urokinase-Type Plasminogen Activator - metabolism</subject><issn>0022-2836</issn><issn>1089-8638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu3CAURVHVKplO8wHdVCy7sQvYOLa6SqJME2mkRkq6RhieM29qgwueVLPrPyRf2C8p1qRZZoUQhwPvXkI-cpZzxqsv23w7tLlgXOaszhmTb8iCs7rJ6qqo35IFY0Jkoi6qY_I-xi1LRFHWR-RYVKLmp5wvyNMt9GAm9I76jl7h_SY76zp0OO3pDYwTWjT0FgI6oDfBT6Aj0Gu3wRYnHyL9jdMm7U2YDyw9R2fR3dNLNwU_7mkX_EA1PdfmZ7bqcaRrbIMO-_mxgx7-_nl8Ea92Mf0kfiDvOt1HOHlel-TH6vLu4ipbf_92fXG2zkwpiikTtjFclsZKbgS0WrRMCyaFZMxqDsbIohWlLUVjteZNwYFZA_q04EIzU-liST4fvGPwv3YQJzVgNND32oHfRZUikpVsmkIklB9QE3yMATo1BhzSJIozNZehtiqVoeYyFKvVHPWSfHrW79oB7MuN_-kn4OsBgDTkA0JQ0SA4AxZDKkVZj6_o_wFq1Z1X</recordid><startdate>20150925</startdate><enddate>20150925</enddate><creator>Sørensen, Hans Peter</creator><creator>Xu, Peng</creator><creator>Jiang, Longguang</creator><creator>Kromann-Hansen, Tobias</creator><creator>Jensen, Knud J.</creator><creator>Huang, Mingdong</creator><creator>Andreasen, Peter A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0085-9141</orcidid></search><sort><creationdate>20150925</creationdate><title>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</title><author>Sørensen, Hans Peter ; Xu, Peng ; Jiang, Longguang ; Kromann-Hansen, Tobias ; Jensen, Knud J. ; Huang, Mingdong ; Andreasen, Peter A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Cell Line</topic><topic>conformation</topic><topic>Crystallography, X-Ray</topic><topic>Drug Discovery</topic><topic>Entropy</topic><topic>fusion protein</topic><topic>glycine</topic><topic>Humans</topic><topic>Mice</topic><topic>Molecular Sequence Data</topic><topic>mupain-1</topic><topic>Peptide Library</topic><topic>Peptides, Cyclic - chemistry</topic><topic>Peptides, Cyclic - metabolism</topic><topic>Peptides, Cyclic - pharmacology</topic><topic>phage display</topic><topic>Protein Conformation</topic><topic>Recombinant Fusion Proteins - chemistry</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>Serine Endopeptidases - chemistry</topic><topic>Serine Endopeptidases - metabolism</topic><topic>Serine Proteinase Inhibitors - chemistry</topic><topic>Serine Proteinase Inhibitors - metabolism</topic><topic>Serine Proteinase Inhibitors - pharmacology</topic><topic>Urokinase-Type Plasminogen Activator - antagonists &amp; inhibitors</topic><topic>Urokinase-Type Plasminogen Activator - chemistry</topic><topic>Urokinase-Type Plasminogen Activator - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sørensen, Hans Peter</creatorcontrib><creatorcontrib>Xu, Peng</creatorcontrib><creatorcontrib>Jiang, Longguang</creatorcontrib><creatorcontrib>Kromann-Hansen, Tobias</creatorcontrib><creatorcontrib>Jensen, Knud J.</creatorcontrib><creatorcontrib>Huang, Mingdong</creatorcontrib><creatorcontrib>Andreasen, Peter A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sørensen, Hans Peter</au><au>Xu, Peng</au><au>Jiang, Longguang</au><au>Kromann-Hansen, Tobias</au><au>Jensen, Knud J.</au><au>Huang, Mingdong</au><au>Andreasen, Peter A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</atitle><jtitle>Journal of molecular biology</jtitle><addtitle>J Mol Biol</addtitle><date>2015-09-25</date><risdate>2015</risdate><volume>427</volume><issue>19</issue><spage>3110</spage><epage>3122</epage><pages>3110-3122</pages><issn>0022-2836</issn><eissn>1089-8638</eissn><abstract>We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy. [Display omitted] •The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26281711</pmid><doi>10.1016/j.jmb.2015.08.005</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0085-9141</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-2836
ispartof Journal of molecular biology, 2015-09, Vol.427 (19), p.3110-3122
issn 0022-2836
1089-8638
language eng
recordid cdi_proquest_miscellaneous_1715659932
source ScienceDirect Freedom Collection
subjects Amino Acid Sequence
Animals
Cell Line
conformation
Crystallography, X-Ray
Drug Discovery
Entropy
fusion protein
glycine
Humans
Mice
Molecular Sequence Data
mupain-1
Peptide Library
Peptides, Cyclic - chemistry
Peptides, Cyclic - metabolism
Peptides, Cyclic - pharmacology
phage display
Protein Conformation
Recombinant Fusion Proteins - chemistry
Recombinant Fusion Proteins - metabolism
Serine Endopeptidases - chemistry
Serine Endopeptidases - metabolism
Serine Proteinase Inhibitors - chemistry
Serine Proteinase Inhibitors - metabolism
Serine Proteinase Inhibitors - pharmacology
Urokinase-Type Plasminogen Activator - antagonists & inhibitors
Urokinase-Type Plasminogen Activator - chemistry
Urokinase-Type Plasminogen Activator - metabolism
title Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T10%3A10%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selection%20of%20High-Affinity%20Peptidic%20Serine%20Protease%20Inhibitors%20with%20Increased%20Binding%20Entropy%20from%20a%20Back-Flip%20Library%20of%20Peptide%E2%80%93Protease%20Fusions&rft.jtitle=Journal%20of%20molecular%20biology&rft.au=S%C3%B8rensen,%20Hans%20Peter&rft.date=2015-09-25&rft.volume=427&rft.issue=19&rft.spage=3110&rft.epage=3122&rft.pages=3110-3122&rft.issn=0022-2836&rft.eissn=1089-8638&rft_id=info:doi/10.1016/j.jmb.2015.08.005&rft_dat=%3Cproquest_cross%3E1715659932%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1715659932&rft_id=info:pmid/26281711&rfr_iscdi=true